UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 26, 2015

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State of incorporation)

 

000-23731
 (Commission
File Number)

 

87-0515089
 (IRS Employer
Identification No.)

 

1400 Kearns Boulevard, 2nd Floor
Park City, Utah
(Address of principal executive offices)

 

84060
(Zip Code)

 

Registrant’s telephone number, including area code: (435) 655-6106

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On January 29, 2015, Nutraceutical International Corporation (“Nutraceutical”) reported results for the fiscal 2015 first quarter ended December 31, 2014.  The press release reporting the results is attached to this Form 8-K as Exhibit 99.1.

 

The press release referenced in this Item 2.02, to the extent that it discusses financial results of Nutraceutical for the quarter ended December 31, 2014, is being furnished pursuant to this Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such filing.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

(a)  On January 26, 2015, Nutraceutical held its 2015 Annual Meeting of Stockholders at which Nutraceutical’s stockholders voted on the three proposals identified below.

 

(b)  The final voting results with respect to each proposal voted upon at the 2015 Annual Meeting of Stockholders are set forth below.  As of December 5, 2014, the record date for the meeting, Nutraceutical had 9,632,428 shares of common stock issued, outstanding and entitled to vote on the proposals.

 

Proposal 1 — Election of Two Class II Directors

 

The stockholders voted to elect the two nominees to the Board of Directors, as set forth below:

 

 

 

For

 

%

 

Withheld

 

%

 

Broker Non-Votes

 

Michael D. Burke

 

7,800,229

 

96.0

 

328,401

 

4.0

 

1,093,140

 

James D. Stice

 

7,800,144

 

96.0

 

328,486

 

4.0

 

1,093,140

 

 

There were no abstentions in the election of directors.

 

Proposal 2 — Ratification of the Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for the Fiscal Year Ending September 30, 2015

 

The stockholders voted to ratify of the selection of PricewaterhouseCoopers LLP as Nutraceutical’s independent registered public accounting firm for the fiscal year ending September 30, 2015 as set forth below:

 

For

 

%

 

Against

 

%

 

Abstentions

 

%

 

8,855,894

 

96.0

 

364,531

 

4.0

 

1,345

 

 

 

2



 

Proposal 3 — Advisory Vote on Named Executive Officer Compensation

 

The stockholders approved, on an advisory basis, Nutraceutical’s compensation of its named executive officers, as set forth below:

 

For

 

%

 

Against

 

%

 

Abstentions

 

%

 

Broker Non-Votes

 

6,046,611

 

74.4

 

1,764,453

 

21.7

 

317,566

 

3.9

 

1,093,140

 

 

Item 9.01 Financial Statements and Exhibits.

 

Nutraceutical herewith files the following documents as exhibits to this Current Report on Form 8-K:

 

(d)     Exhibits

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press release issued by Nutraceutical dated January 29, 2015

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

(Registrant)

 

 

 

By:

                    /s/ Cory J. McQueen

Date: January 29, 2015

 

 

 

 

Cory J. McQueen
Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

 

4



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1

 

Press release issued by Nutraceutical dated January 29, 2015

 

5




Exhibit 99.1

 

FOR:

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

 

 

CONTACT:

 

Cory McQueen

 

 

Vice President and

 

 

Chief Financial Officer

 

 

(435) 655-6106

 

NUTRACEUTICAL REPORTS FISCAL 2015 Q1 RESULTS

 

PARK CITY, Utah, January 29, 2015/PRNewswire/—Nutraceutical International Corporation (NASDAQ:  NUTR) today reported results for the fiscal 2015 first quarter ended December 31, 2014.  Net sales for the fiscal 2015 first quarter were $53.0 million compared to $51.6 million for the same quarter of fiscal 2014.  For the first quarter of fiscal 2015, net income was $3.4 million, or $0.35 diluted earnings per share, compared to net income of $4.1 million, or $0.42 diluted earnings per share, for the same quarter of fiscal 2014.

 

Operating cash flow for the fiscal 2015 first quarter was $3.0 million compared to $5.5 million for the same period of fiscal 2014.  The fiscal 2015 first quarter operating cash flow, combined with existing cash, was primarily used to invest $2.6 million in purchases of property, plant and equipment, $1.1 million in purchases of common stock for treasury and to repay net borrowings of $1.0 million on the Company’s revolving credit facility.

 

Bill Gay, chairman and chief executive officer, commented, “Our fiscal 2015 first quarter net sales growth of 2.9% was primarily the result of fiscal 2014 acquisitions. Non-acquisition net sales during the quarter were down slightly as a result of increased product out-of-stocks and some health food store market softness.   Reducing out-of-stocks is a key priority. We continue to anticipate operational synergies and further net sales growth from the fiscal 2014 acquisitions in the later part of 2015.”

 

Mr. Gay stated, “Adjusted EBITDA remained strong, although it decreased from the comparable fiscal 2014 quarter as a result of lower gross margins and increases in marketing, selling and distribution expenses, which came principally from the integration of fiscal 2014 acquisitions.  The decrease in fiscal 2015 quarterly net income was primarily a result of increased amortization and depreciation expense relating to acquisitions and capital investments in equipment.”

 

Mr. Gay continued, “Management is confident that its ongoing focus to integrate the fiscal 2014 acquisitions, decrease out-of-stocks, reduce inventory, consolidate labor, redirect

 



 

promotional efforts, introduce strong new products and more effectively utilize its sales force will provide a foundation for desired cost synergies and sustainable growth over the coming years. Acquisitions are critically important to our growth and this will not change.  Integration of acquisitions has been a core competency over many years, although the fiscal 2014 acquisitions have been particularly challenging. Management appreciates the ongoing strategic long-term growth perspective our customers, employees and stockholders provide as we continue to enhance and grow our business.”

 

ABOUT NUTRACEUTICAL

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores.  Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.  Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements.  We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

 

We manufacture and sell nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Nature’s Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.

 

We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom’s Natural Foods™ and Cornucopia Community Market™.  We also own health food stores, which operate under various trade names including Fresh Vitamins™, Granola’s™ and Peachtree Natural Foods®.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 8,000 SKUs, including approximately 800 SKUs exclusively sold internationally.  We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These

 



 

forward-looking statements can be identified by the use of terms such as “believe,” “expects,” “plan,” “intend,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements.  Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions,  inability to complete them or inability to integrate them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types,  (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.  Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC’s website (www.sec.gov).

 

# # #

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

 

 

 

December 31,

 

September 30,

 

 

 

2014

 

2014

 

Assets

 

 

 

 

 

Current assets, net

 

$

80,665

 

$

83,850

 

Property, plant and equipment, net

 

79,870

 

79,244

 

Goodwill

 

23,622

 

23,622

 

Other non-current assets, net

 

27,743

 

28,062

 

 

 

$

211,900

 

$

214,778

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

$

17,393

 

$

21,709

 

Long-term liabilities

 

42,310

 

43,456

 

Stockholders’ equity

 

152,197

 

149,613

 

 

 

$

211,900

 

$

214,778

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

 

 

 

Three months ended December 31,

 

 

 

2014

 

2013

 

Net sales

 

$

53,044

 

$

51,550

 

Cost of sales

 

27,189

 

25,488

 

Gross profit

 

25,855

 

26,062

 

Operating expenses

 

 

 

 

 

Selling, general and administrative

 

19,554

 

18,581

 

Amortization of intangible assets

 

732

 

584

 

Income from operations

 

5,569

 

6,897

 

Interest and other expense, net

 

297

 

318

 

Income before provision for income taxes

 

5,272

 

6,579

 

Provision for income taxes

 

1,921

 

2,444

 

 

 

 

 

 

 

Net income

 

$

3,351

 

$

4,135

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

Basic

 

$

0.35

 

$

0.42

 

Diluted

 

0.35

 

0.42

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

Basic

 

9,653,113

 

9,837,631

 

Diluted

 

9,660,007

 

9,847,659

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

ADJUSTED EBITDA SCHEDULE

(unaudited; dollars in thousands)

 

 

 

Three months ended December 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Net income

 

$

3,351

 

$

4,135

 

Provision for income taxes

 

1,921

 

2,444

 

Interest and other expense, net (1)

 

297

 

318

 

Depreciation and amortization

 

3,239

 

2,638

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

8,808

 

$

9,535

 

 


(1)   Includes amortization of deferred financing fees.

 

Non-GAAP Financial Measures

 

Adjusted EBITDA (a non-GAAP measure) is defined in our performance measures as earnings before net interest and other expense, taxes, depreciation, amortization and goodwill and intangible asset impairments.  We believe that Adjusted EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance.  Adjusted EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation.  Furthermore, Adjusted EBITDA is not intended to be an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.

 


Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.
Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.